glp-1 receptor agonist antipsychotic weight gain study Induced and Metabolic Dysfunction GLP-1 Receptor Agonists in Mood

In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said that they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity

The drug is not recommended for anyone who is pregnant or who may become pregnant

Kahle, M

Given these risks, many individuals are seeking natural alternatives to Ozempic for weight management and metabolic health, especially those who are not diabetic but are using Ozempic off-label for weight loss

Additionally, GLP-1 reduces the release of glucagon, another hormone produced by the pancreas, which typically signals the liver to release stored glucose

In the ELIXA and the EXSCEL trials, GLP-1RAs (once daily lixisenatide and once weekly exenatide, respectively) didnt provide benefit in MACE reduction compared to placebo, but were non-inferior to placebo for the primary composite outcome of MACE